Evolocumab公司
医学
心脏病学
心肌梗塞
内科学
他汀类
临床试验
载脂蛋白B
胆固醇
载脂蛋白A1
作者
Stephen J. Nicholls,Y. Kataoka,S. Nissen,F. Prati,Stephan Windecker,R. Puri,T. Hucko,D. Aradi,J. Herrman,R. Hermanides,B. Wang,H. Wang,J. Butters,G. Di Giovanni,S. Jones,G. Pompili,P. Psaltis
标识
DOI:10.1016/j.hlc.2022.06.335
摘要
The impact of intensive lowering therapy after acute coronary syndromes (ACS) with statins with or without proprotein convertase subtilisin kexin type-9 (PCSK9) inhibitors on coronary atheroma phenotype is unknown.
科研通智能强力驱动
Strongly Powered by AbleSci AI